Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Mouse Explants Generated from Patients' Circulating Tumor Cells Pave Way for Directed Personalized Chemotherapy

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Cancer researchers have isolated circulating tumor cells (CTCs) from patients with small-cell lung cancer (SCLC) and implanted them into immunocompromised mice to use as a model system for developing better treatments for the disease.

SCLC is an aggressive neuroendocrine tumor with early dissemination and poor prognosis that accounts for 15%–20% of lung cancer cases and approximately 200,000 deaths in the United Kingdom each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. A more promising approach for studying SCLC is by collecting "liquid biopsy" specimens—CTCs, which are prevalent in the blood of SCLC patients.

Investigators at the University of Manchester (United Kingdom) reported in June 1, 2014, online edition of the journal Nature Medicine that CTCs from SCLC patients who either responded to chemotherapy or failed to respond to chemotherapy developed into tumors in immunocompromised mice. The resultant CTC-derived explants (CDXs) mirrored the donor patient's response to platinum and etoposide chemotherapy. Genomic analysis of isolated CTCs revealed considerable similarity to the corresponding CDX.

Senior author Dr. Caroline Dive, professor of pharmacology and pharmacy at the University of Manchester, said, “Access to sufficient tumor tissue is a major barrier to fully understanding the biology of SCLC. This liquid biopsy is straightforward and not invasive so can be easily repeated and will allow us to study the genetics of each lung cancer patient’s individual tumor. It also means that we may have a feasible way of monitoring patient response to therapy, hopefully allowing us to personalize and tailor individual treatment plans to each patient. We can use these models to help us understand why so many SCLC patients acquire resistance to chemotherapy and to search for and test potential new targeted treatments.”

Related Links:

University of Manchester



BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.